Reset Therapeutics

About Reset Therapeutics

Reset Therapeutics, Inc., also known as Reset Pharma, is a neuro-biotechnology company founded in 2020 by Philip Taub and Jan-Anders Karlsson. The company focuses on developing psilocybin-inspired therapies to address mental health conditions, particularly demoralization syndrome, in patients with life-altering diseases like cancer. Reset Pharma is developing RSTP1000, an oral psilocybin treatment, as its lead program to treat cancer-related demoralization, anxiety, and depression.

The company's strategy is based on the premise that psychedelics can reset neural networks in the brain. To advance its research, Reset Pharma has acquired an exclusive worldwide license from NYU Langone Health for intellectual property related to the use of psilocybin and similar psychedelics for treating mental illness in patients with life-threatening diseases. This license is based on the work of Dr. Stephen Ross, a prominent researcher in psychedelic medicine and psycho-oncology. The business model targets a significant unmet need, as demoralization syndrome affects a large number of cancer patients and currently has no approved treatments.

Reset Pharma is a privately held, venture capital-backed company. It has raised a total of $11.1 million in funding over one Series B round on February 16, 2022, with investors including Merida Capital Partners, Palo Santo, and PsyMed Ventures. The company is headquartered in Great Neck, New York, and is preparing for the next phase of growth by advancing its programs toward clinical trials, having filed an Investigational New Drug (IND) application with the FDA in 2023.